House Bill 934 Summary

• Expands North Carolina's Right to Try Act to authorize eligible patients with terminal or severe chronic diseases to access investigational adult stem cell treatments under institutional review board oversight.

• Eligible patients must have considered all FDA-approved treatment options, received physician recommendation, provided written informed consent, and have documentation of eligibility from treating physician.

• Requires treatments to be administered by physicians certified by institutional review boards affiliated with accredited medical schools in North Carolina, with annual reporting to the North Carolina Medical Board.

• Prohibits the knowing purchase and sale of adult stem cells for valuable consideration in investigational treatments, with exceptions for standard medical fees, legal/medical expense reimbursement, and donor travel/housing costs; violations are Class A1 misdemeanors.

• Protects physicians from licensing board disciplinary action and prevents government interference with eligible patients' access to authorized treatments, provided care meets applicable standards and requirements.